Citi has adjusted its price target for Argenx (ARGX, Financial), increasing it significantly from $681 to $796. The firm maintains its Buy rating on Argenx shares, citing strong fundamentals, imminent catalysts, and potential for acquisition as factors likely to attract investor attention.
In the face of widespread macroeconomic uncertainties that have been pressuring small-cap biotechnology stocks, Citi highlights Argenx as a standout within the sector. The company is continuing to see growth in revenues from its product Vyvgart, with additional expansion opportunities anticipated. This positions Argenx favorably in a challenging investment landscape.